These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36113407)

  • 1. CtDNA-guided rechallenge with anti-EGFR therapy in RASwt metastatic colorectal cancer: Evidence from clinical practice.
    D'Onofrio R; Caputo F; Prampolini F; Spallanzani A; Gelsomino F; Bettelli S; Manfredini S; Reggiani Bonetti L; Carotenuto P; Bocconi A; Dominici M; Luppi G; Salati M
    Tumori; 2023 Aug; 109(4):387-393. PubMed ID: 36113407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis.
    Vlachou MS; Mauri D; Zarkavelis G; Ntellas P; Tagkas C; Gkoura S; Pentheroudakis G
    Exp Oncol; 2021 Sep; 43(3):252-256. PubMed ID: 34591420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
    Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
    JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review.
    Ciardiello D; Mauri G; Sartore-Bianchi A; Siena S; Zampino MG; Fazio N; Cervantes A
    Cancer Treat Rev; 2024 Mar; 124():102683. PubMed ID: 38237253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.
    Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A
    Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
    Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
    JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Validation of Plasma-Based Genotyping for
    Aoki Y; Nakamura Y; Denda T; Ohta T; Esaki T; Shiozawa M; Yamaguchi K; Yamazaki K; Sunakawa Y; Kato T; Okano N; Taniguchi H; Sato T; Oki E; Nishina T; Komatsu Y; Matsuhashi N; Goto M; Yasui H; Ohtsubo K; Moriwaki T; Takahashi N; Horita Y; Boku S; Wakabayashi M; Ikeno T; Mitani R; Yuasa M; Yoshino T
    JCO Precis Oncol; 2023 Jun; 7():e2200688. PubMed ID: 37343204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
    Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E
    Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Sunakawa Y; Nakamura M; Ishizaki M; Kataoka M; Satake H; Kitazono M; Yanagisawa H; Kawamoto Y; Kuramochi H; Ohori H; Nakamura M; Maeda F; Komeno C; Sonezaki T; Takeuchi M; Fujii M; Yoshino T; Tsuji A; Ichikawa W
    JCO Precis Oncol; 2020 Nov; 4():898-911. PubMed ID: 35050760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis.
    Rossini D; Germani MM; Pagani F; Pellino A; Dell'Aquila E; Bensi M; Liscia N; Moretto R; Boccaccino A; Prisciandaro M; Manglaviti S; Schirripa M; Vivolo R; Scartozzi M; Santini D; Salvatore L; Pietrantonio F; Loupakis F; Falcone A; Cremolini C
    Clin Colorectal Cancer; 2020 Sep; 19(3):191-199.e6. PubMed ID: 32466976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry.
    Chong LC; Hardingham JE; Townsend AR; Piantadosi C; Rico GT; Karapetis C; Padbury R; Maddern G; Roy A; Price TJ
    Target Oncol; 2020 Dec; 15(6):751-757. PubMed ID: 33068283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study.
    Vidal J; Fernández-Rodríguez MC; Casadevall D; García-Alfonso P; Páez D; Guix M; Alonso V; Cano MT; Santos C; Durán G; Elez E; Manzano JL; Garcia-Carbonero R; Ferreiro R; Losa F; Pineda E; Sastre J; Rivera F; Bellosillo B; Tabernero J; Aranda E; Salazar R; Montagut C;
    Clin Cancer Res; 2023 Jan; 29(2):379-388. PubMed ID: 36074154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).
    Sunakawa Y; Satake H; Usher J; Jaimes Y; Miyamoto Y; Nakamura M; Kataoka M; Shiozawa M; Takagane A; Terazawa T; Watanabe T; Ishiguro K; Tanaka C; Takeuchi M; Fujii M; Danenberg K; Danenberg PV; Lenz HJ; Sekikawa T; Ichikawa W
    ESMO Open; 2022 Jun; 7(3):100512. PubMed ID: 35688061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
    Grasselli J; Elez E; Caratù G; Matito J; Santos C; Macarulla T; Vidal J; Garcia M; Viéitez JM; Paéz D; Falcó E; Lopez Lopez C; Aranda E; Jones F; Sikri V; Nuciforo P; Fasani R; Tabernero J; Montagut C; Azuara D; Dienstmann R; Salazar R; Vivancos A
    Ann Oncol; 2017 Jun; 28(6):1294-1301. PubMed ID: 28368441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer.
    Sorah JD; Moore DT; Reilley MJ; Salem ME; Triglianos T; Sanoff HK; McRee AJ; Lee MS
    Oncologist; 2022 Dec; 27(12):1006-e930. PubMed ID: 36288238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials.
    Ciardiello D; Napolitano S; Famiglietti V; Esposito L; De Falco V; Di Liello A; Avallone A; Maiello E; Pietrantonio F; Cremolini C; Zampino MG; Fazio N; Troiani T; Martinelli E; Ciardiello F; Martini G
    Cancers (Basel); 2023 Apr; 15(7):. PubMed ID: 37046778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
    Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR
    Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Trial Protocol of Precision Medicine for Patients with RAS Wild Metastatic Colorectal Cancer Using Liquid Biopsy (RAS-liquid Study): A Prospective, Multicenter Observational Study.
    Matsuda A; Yamada T; Takahashi T; Hirata K; Nagasaka T; Ishimaru K; Sakamoto K; Koda K; Ishikawa T; Ishida H; Matsuda K; Kuramochi H; Yoshida Y; Sonoda H; Yoshida H
    J Anus Rectum Colon; 2022; 6(1):52-57. PubMed ID: 35128137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.